Navigation Links
Matrixx Initiatives, Inc. Reports Fiscal 3rd Quarter Net Sales of $30.8 Million and Net Loss of ($0.07) Per Share
Date:1/30/2008

31, 2008; (ii) our belief that seasonal buying patterns have changed; (iii) our belief that our sales force will improve product distribution and lower sales expense; (iv) our expectation of improving our gross margins in the future; (v) our expectations regarding product liability defense costs; and (vi) our expectations regarding new products. These forward-looking statements are based on the Company's current expectations and are subject to a number of risks and uncertainties, many of which cannot be predicted or quantified and are beyond the Company's control. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. Factors that could cause actual results to differ materially from the Company's expectations include: (a) the severity and timing of the cold season; (b) the possibility that future sales of our products will not be as strong as expected; (c) the possibility that supply issues may impact future sales of our products; (d) the possibility that our products may face increased competition or negative publicity; (e) the potential impact of current and future product liability litigation; (f) regulatory issues or public relations challenges; (g) the possibility of delays or other difficulties in implementing new product improvements and introducing to the marketplace new products and brands; (h) and the possibility that expenses, including legal expenses, product reserves, and expenses associated with adverse litigation outcomes, may exceed budgeted amounts. Other factors that could cause actual results to differ materially from the Company's expectations are described in the Company's Transition Report on Form 10-KT filed on May 30, 2007, under the heading "Risk Factors," filed pursuant to the Securities Exchange Act of 1934. We do not undertake, and we specifically disclaim, any obligation to publicly update or revise any forward-looking statement whether as a result
'/>"/>
SOURCE Matrixx Initiatives, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. Matrixx Initiatives, Inc. Sets Time for Discussion of Third Quarter Fiscal 2008 Financial Results
2. Matrixx Initiatives, Inc. Updates 2007/2008 Cold Season Trends and Fiscal 2008 Sales and Earnings Outlook
3. Matrixx Initiatives, Inc. to Present at the William Blair & Company Small-Cap Growth Stock Conference
4. Matrixx Initiatives, Inc. to Present at the Roth Capital Partners 2007 New York Conference
5. Accuray Reports Continued Growth in Second Quarter of Fiscal 2008
6. Cardinal Health Reports Second Quarter Results, Revises EPS Outlook
7. Encision Reports Third Fiscal Quarter Results
8. Zimmer Reports Fourth Quarter and 2007 Financial Results
9. Amylin Pharmaceuticals Reports 2007 Financial Results
10. Cystic Fibrosis Foundation reports upward trend for key health outcomes
11. NBTY Reports First Quarter Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... Explorys, the leader in big data-driven healthcare ... Greg Yarrington as Vice President of Operations, Adam Wallace ... Vice President of Solutions. These new leaders are part ... 2015 to support client demand for the company’s big ... growth of its partner network. , Since the ...
(Date:12/22/2014)... The MedTech industry is gearing up for new growth ... PartnerTech AB of Sweden, is prepared to facilitate the manufacturing ... , All signs point to growth in the MedTech industry ... repeal of the excise tax originally levied to fund the ... growth of 9.3% and PartnerTech Inc. is prepared to answer ...
(Date:12/22/2014)... Branch, TX (PRWEB) December 22, 2014 ... revolutionary work glove with many useful features. Customers of ... and can have the new gloves delivered to their ... work gear and hand tools that incorporate heavy duty ... Utility Magnetic Glove allows workers to store metal parts ...
(Date:12/22/2014)... December 22, 2014 NAPW ... Professional Woman of the Year. She is recognized with ... largest, most recognized networking organization of professional women in ... National Association of Professional Women is a vibrant networking ... Chapters. , Ms. Kreider is passionate and committed to ...
(Date:12/22/2014)... Parker & Sons, Inc. a reliable and dependable ... services reports a record number of favorable reviews and ... As a company that has served the greater Phoenix ... is a business that is focused on excellent credibility ... top quality companies in Arizona that are focused on ...
Breaking Medicine News(10 mins):Health News:Explorys Continues to Experience Rapid Growth, Adds Three Healthcare IT Executives to Its Leadership Team 2Health News:Explorys Continues to Experience Rapid Growth, Adds Three Healthcare IT Executives to Its Leadership Team 3Health News:PartnerTech Inc. Poised for Growth in MedTech 2Health News:MagnoGrip Pro Utility Magnetic Gloves on Sale at TheHardwareCity.com 2Health News:National Association of Professional Women Announces Cheryl A. Kreider, President / CEO of Kreider Health Solutions, LLC, a 2014 Professional Woman of the Year 2Health News:Parker & Sons Reports A Record Number Of Favorable References With Regard To Its Quality Services In 2014 2Health News:Parker & Sons Reports A Record Number Of Favorable References With Regard To Its Quality Services In 2014 3
... fruitful, lead in ongoing investigation into salmonella outbreak , , ... U.S. government investigation into salmonella-tainted tomatoes has not yet ... said Monday they are now focusing their trace-back efforts ... , "The cluster is linked to the same ...
... PITTSBURGH, June 16 Mylan Inc. (NYSE: ... Inc., has,received tentative approval from the U.S. Food ... Application (ANDA) for Irbesartan and,Hydrochlorothiazide Tablets, 150 mg/12.5 ... Hydrochlorothiazide Tablets, indicated for the treatment,of hypertension, are ...
... have found a new family of therapeutic agents that ... growth of breast cancer cells. The results of the ... The Endocrine Society,s 90th Annual Meeting in San Francisco. ... therapeutic called TPBM and related compounds are likely to ...
... of agents that inhibit the growth of estrogen-dependent breast ... of the Endocrine Society, has opened an avenue of ... , "This cell-based study is exciting because it suggests ... that remain dependent on estrogen for growth but are ...
... could be the next generation of treatments, researchers say ... identified a new group of compounds that might one ... to fight estrogen-fueled breast cancer. , "This is a ... Dr. Len Lichtenfeld, deputy chief medical officer of the ...
... June 16 The National Center for Healthcare,Leadership ... Gabow, MD, chief,executive officer of Denver Health, as ... for her significant and lasting contributions,to healthcare. Under ... healthcare system that achieves organizational,excellence while treating at-risk ...
Cached Medicine News:Health News:FDA Narrowing Tainted Tomato Probe to One Cluster 2Health News:FDA Narrowing Tainted Tomato Probe to One Cluster 3Health News:Future hope for patients with breast cancers resistant to tamoxifen 2Health News:Team discovers new inhibitors of estrogen-dependent breast cancer cells 2Health News:New Molecule Discovery Shows Promise Against Tamoxifen-Resistant Breast Cancers 2Health News:Denver Health's Dr. Patricia Gabow Receives NCHL's 2008 National Healthcare Leadership Award 2Health News:Denver Health's Dr. Patricia Gabow Receives NCHL's 2008 National Healthcare Leadership Award 3Health News:Denver Health's Dr. Patricia Gabow Receives NCHL's 2008 National Healthcare Leadership Award 4
(Date:12/22/2014)...  Mark Farrah Associates (MFA), www.markfarrah.com , ... the 2015 marketplace exchange projections and insights about ... According to a recent ASPE (Office of the ... Health and Human Services) report, an estimated 6.7 ... through the Marketplace as of October 2014 and ...
(Date:12/22/2014)... 22, 2014  Pfenex Inc. (NYSE MKT: PFNX) today ... has been filed and is now open and that ... Department of Health and Human Services (HHS), through the ... "We are extremely pleased to have the IND now ... a significant milestone in our company,s partnership with BARDA ...
(Date:12/22/2014)... Dec. 22, 2014 TWi Biotechnology, Inc., ... Allowance for AC-201, TWi Biotechnology,s lead drug candidate, ... China for patent application numbered ... acceptable salts, active metabolite for treatment of type ... of treatment using AC-201 for type II diabetes, ...
Breaking Medicine Technology:Insights into the Marketplace and Individual Market Growth 2Pfenex Announces Active IND and Additional BARDA Funding for Recombinant Anthrax Vaccine Program, Px563L 2Pfenex Announces Active IND and Additional BARDA Funding for Recombinant Anthrax Vaccine Program, Px563L 3TWi Biotechnology Receives Notice of Patent Allowance for Its Lead Drug Candidate AC-201 for the Indication of Type II Diabetes in China 2TWi Biotechnology Receives Notice of Patent Allowance for Its Lead Drug Candidate AC-201 for the Indication of Type II Diabetes in China 3
... 7 Aerovance Inc. today reported,pharmacokinetic (PK) and ... its Aerovant,inhalation powder that demonstrate good tolerability with ... of a single 10 mg,dose., This 10 ... doses investigated in,Aerovance,s Phase IIb dose-ranging study, which ...
... Menu Expanded to Eight On-Demand Tests for Use on the GeneXpert(R) ... ... 7 Cepheid (Nasdaq:,CPHD) today announced the release of Xpert(TM) vanA/vanB as ... Diagnostic,Medical Devices. The test delivers rapid detection of vanA and/or vanB,genes, the ...
Cached Medicine Technology:Data Show Aerovance's Aerovant(TM) Inhalation Powder is Well Tolerated in Asthma Patients 2Cepheid Announces CE IVD Release of First On-Demand Test for van A/van B Genes Most Associated With Hospital-Acquired VRE Infection 2Cepheid Announces CE IVD Release of First On-Demand Test for van A/van B Genes Most Associated With Hospital-Acquired VRE Infection 3Cepheid Announces CE IVD Release of First On-Demand Test for van A/van B Genes Most Associated With Hospital-Acquired VRE Infection 4
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: